Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · IEX Real-Time Price · USD
21.86
-0.11 (-0.50%)
At close: May 2, 2024, 4:00 PM
21.70
-0.16 (-0.73%)
After-hours: May 2, 2024, 5:59 PM EDT
Syndax Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
184
Market Cap
1.86B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 139.71M | 138.19M | 9,109.56% |
Dec 31, 2020 | 1.52M | - | - |
Dec 31, 2019 | 1.52M | - | - |
Dec 31, 2018 | 1.52M | -591.00K | -28.04% |
Dec 31, 2017 | 2.11M | 888.00K | 72.79% |
Dec 31, 2016 | 1.22M | 593.00K | 94.58% |
Dec 31, 2015 | 627.00K | - | - |
Dec 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Owens & Minor | 10.33B |
Amneal Pharmaceuticals | 2.39B |
Galapagos NV | 266.36M |
Schrödinger | 188.48M |
Recursion Pharmaceuticals | 44.58M |
Avadel Pharmaceuticals | 27.96M |
Agios Pharmaceuticals | 26.82M |
NewAmsterdam Pharma Company | 15.66M |
SNDX News
- 2 days ago - Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 - PRNewsWire
- 22 days ago - Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum - PRNewsWire
- 25 days ago - Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session - PRNewsWire
- 27 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 5 weeks ago - Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia - PRNewsWire
- 5 weeks ago - Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia - PRNewsWire
- 6 weeks ago - Syndax Announces Appointment of Steven Closter as Chief Commercial Officer - PRNewsWire
- 2 months ago - Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update - PRNewsWire